**Press Release – No. 4 / 2016**

# Zealand informs of new data on iGlarLixi and proprietary preclinical peptide drug candidates to be presented at the 76th Annual American Diabetes Associations Scientific Sessions

- **First time presentations at a scientific congress of results from the two pivotal Phase III trials, LixiLan-L and LixiLan-O, with iGlarLixi**
- **Presentations in two oral sessions on Sunday, 12 June 2016**

*Copenhagen, 8 June 2016* – Zealand informs that new Phase III data will be presented on iGlarLixi, the fixed-ratio titratable combination of insulin glargine 100 Units/mL (Lantus®) and lixisenatide, at the upcoming 76th Scientific Sessions of the American Diabetes Association (ADA), taking place 10-14 June 2016 in New Orleans, the United States. This is the first time results from these pivotal trials are being presented at a scientific congress.

Further at ADA, Zealand will present new data from its proprietary preclinical activities, including on a novel peptide drug candidate from its preclinical pipeline.

Abstracts of the ADA presentations are available at: http://app.core-apps.com/tristar_ada16

## IGlarLixi – Oral presentations of results from two pivotal Phase III trials, LixiLan-O and LixiLan-L

Presentation of results from LixiLan-O (# 186-OR):

"*Clinical Impact of Titratable Fixed-Ratio Combination of Insulin Glargine/Lixisenatide vs. Each Component Alone in Type 2 Diabetes Inadequately Controlled on Oral Agents: LixiLan-O Trial*"

When: Sunday, 12 June 2016 at 8.45 am CDT
Presenter: Julio Rosenstock, MD, Dallas Diabetes and Endocrine Center
Location: La Nouvelle Orleans AB
Link to abstract: http://app.core-apps.com/tristar_ada16/event/2dcea2d3f4cca64c82bb162014ab0feb

Presentation of results from LixiLan-L (# 238-OR):

"*Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Patients with T2DM: The LixiLan-L Trial*"

When: Sunday, 12 June 2016 at 2.30 pm CDT
Presenter: Vanita R. Aroda, MD, Medstar Health Research Institute
Location: La Nouvelle Orleans AB
Link to abstract: http://app.core-apps.com/tristar_ada16/event/9b73fdfd4b7befbd3fa1b130a88c5086

## Zealand poster presentations

Zealand scientists will present posters with new data from two of the company's proprietary preclinical peptide drug projects:

*"Antidiabetic Effects of Novel, Long-Acting Amylin Analogue ZP4982 in ZDF Rats" (# 283-LB)*

When: 12 June 2016 at 12 pm CDT
Presenter: Jolanta Skarbaliene, Zealand, Denmark
Location: Poster Hall (D-E)
Link to abstract: http://app.core-apps.com/tristar_ada16/abstract/e44e3c20f4b9cf62bd1796c12c19074b

***"****Model of the Glucose-Insulin-Glucagon Dynamics after Subcutaneous Administration of a Glucagon Rescue Bolus in Healthy Humans" (# 1759-P)*

When: 12 June 2016 at 12 pm CDT
Presenter: Sabrina L. Wendt, Zealand, Denmark
Location: Poster Hall (D-E)
Link to abstract: http://app.coreapps.com/tristar_ada16/abstract/92b0eac0f984437a5bebc08c57a7b135

## For further information, please contact:

**Britt Meelby Jensen,** President and Chief Executive Officer
Tel: +45 51 67 61 28, email: bmj@zealandpharma.com

**Hanne Leth Hillman,** Senior Vice President, Investor Relations and Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

### About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company with leading scientific expertise in turning peptides into medicines. Zealand has a pipeline of proprietary drug candidates which target specialty disease areas with significant unmet medical needs and a portfolio of medicines and product candidates under license collaborations with Sanofi, Helsinn and Boehringer Ingelheim.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of Type 2 diabetes, is licensed to Sanofi who markets the product globally outside the US as Lyxumia®. Lixisenatide is under regulatory review in the US. The fixed-ratio combination of basal insulin glargine (Lantus®) and lixisenatide, referred to as iGlarLixi, is under regulatory review in the US and Europe.

Zealand's proprietary pipeline of product candidates includes: *ZP4207 (single-dose rescue treatment*) for acute, severe hypoglycemia (Phase II); *ZP1848* for short bowel syndrome (Phase II); *ZP4207 (multiple-dose version)* intended for use in a dual-hormone artificial pancreas system for better hypoglycemia management in diabetes (Phase I); *ZP2929* for diabetes/obesity (Phase I); and several preclinical peptide therapeutics.

The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand's business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma